Tags

Type your tag names separated by a space and hit enter

The clinical efficacy of fluticasone propionate combined with ACEI/ARB in the treatment of immunoglobulin A nephropathy.
BMC Nephrol. 2023 03 22; 24(1):63.BN

Abstract

BACKGROUND

Immunoglobulin A nephropathy (IgAN) is the most common primary glomerulopathy worldwide, and lacks the effective treatment. The study was aimed to investigate the clinical efficacy of fluticasone propionate aerosol combined with angiotensin converting enzyme inhibitor / angiotensin receptor blocker (ACEI/ARB) in the treatment of IgAN.

METHODS

142 patients with biopsy-proven IgAN at Shenzhen People?s hospital from June 2018 to June 2020 were enrolled. The patients were randomly divided into the supportive care plus fluticasone group and the supportive care group. The patients of the supportive care plus fluticasone group were treated with fluticasone propionate aerosol (250 ?g Bid) combined with ACEI/ARB, while the supportive care group was merely treated with ACEI/ARB. The patients were followed up at 3, 6 and 9 months after enrollment. Primary outcomes include changes in proteinuria and estimated glomerular filtration rate (eGFR).

RESULTS

The level of proteinuria in the supportive care plus fluticasone group was significantly lower compared with the supportive care group at 0, 3, 6 and 9 months. Meanwhile, during the follow-up period, no serious adverse events were recorded during the study in either group. However, fluticasone treatment did not alleviate the decline in eGFR.

CONCLUSION

Fluticasone propionate aerosol combined with ACEI/ARB can reduce the level of proteinuria in thetreatment of IgAN, and has no significant effects on renal function.

Links

PMC Free PDF

Authors+Show Affiliations

Sun L
Department of Nephrology, Shenzhen Key Laboratory of Renal, Shenzhen People's Hospital, The Second Clinical Medical College, Jinan University, Guangzhou, China. sun130523@163.com. The First Affiliated Hospital, Southern University of Science and Technology, Shenzhen, Guangdong, 518020, China. sun130523@163.com.
Zi X
Department of Nephrology, Shenzhen Key Laboratory of Renal, Shenzhen People's Hospital, The Second Clinical Medical College, Jinan University, Guangzhou, China.
Wang Z
Department of Nephrology, Shenzhen Key Laboratory of Renal, Shenzhen People's Hospital, The Second Clinical Medical College, Jinan University, Guangzhou, China.
Zhang X
Department of Nephrology, Shenzhen Key Laboratory of Renal, Shenzhen People's Hospital, The Second Clinical Medical College, Jinan University, Guangzhou, China.

MeSH

HumansGlomerulonephritis, IGAAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsFluticasoneProteinuriaTreatment OutcomeGlomerular Filtration Rate

Pub Type(s)

Randomized Controlled Trial
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

36949400

Citation

Sun, Liping, et al. "The Clinical Efficacy of Fluticasone Propionate Combined With ACEI/ARB in the Treatment of Immunoglobulin a Nephropathy." BMC Nephrology, vol. 24, no. 1, 2023, p. 63.
Sun L, Zi X, Wang Z, et al. The clinical efficacy of fluticasone propionate combined with ACEI/ARB in the treatment of immunoglobulin A nephropathy. BMC Nephrol. 2023;24(1):63.
Sun, L., Zi, X., Wang, Z., & Zhang, X. (2023). The clinical efficacy of fluticasone propionate combined with ACEI/ARB in the treatment of immunoglobulin A nephropathy. BMC Nephrology, 24(1), 63. https://doi.org/10.1186/s12882-023-03106-4
Sun L, et al. The Clinical Efficacy of Fluticasone Propionate Combined With ACEI/ARB in the Treatment of Immunoglobulin a Nephropathy. BMC Nephrol. 2023 03 22;24(1):63. PubMed PMID: 36949400.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The clinical efficacy of fluticasone propionate combined with ACEI/ARB in the treatment of immunoglobulin A nephropathy. AU - Sun,Liping, AU - Zi,Xinyi, AU - Wang,Zhen, AU - Zhang,Xinzhou, Y1 - 2023/03/22/ PY - 2022/07/15/received PY - 2023/03/06/accepted PY - 2023/3/23/entrez PY - 2023/3/24/pubmed PY - 2023/3/25/medline KW - Clinical efficacy KW - Fluticasone propionate aerosol KW - IgA nephropathy KW - Proteinuria SP - 63 EP - 63 JF - BMC nephrology JO - BMC Nephrol VL - 24 IS - 1 N2 - BACKGROUND: Immunoglobulin A nephropathy (IgAN) is the most common primary glomerulopathy worldwide, and lacks the effective treatment. The study was aimed to investigate the clinical efficacy of fluticasone propionate aerosol combined with angiotensin converting enzyme inhibitor / angiotensin receptor blocker (ACEI/ARB) in the treatment of IgAN. METHODS: 142 patients with biopsy-proven IgAN at Shenzhen People?s hospital from June 2018 to June 2020 were enrolled. The patients were randomly divided into the supportive care plus fluticasone group and the supportive care group. The patients of the supportive care plus fluticasone group were treated with fluticasone propionate aerosol (250 ?g Bid) combined with ACEI/ARB, while the supportive care group was merely treated with ACEI/ARB. The patients were followed up at 3, 6 and 9 months after enrollment. Primary outcomes include changes in proteinuria and estimated glomerular filtration rate (eGFR). RESULTS: The level of proteinuria in the supportive care plus fluticasone group was significantly lower compared with the supportive care group at 0, 3, 6 and 9 months. Meanwhile, during the follow-up period, no serious adverse events were recorded during the study in either group. However, fluticasone treatment did not alleviate the decline in eGFR. CONCLUSION: Fluticasone propionate aerosol combined with ACEI/ARB can reduce the level of proteinuria in thetreatment of IgAN, and has no significant effects on renal function. SN - 1471-2369 UR - https://www.unboundmedicine.com/medline/citation/36949400/The_clinical_efficacy_of_fluticasone_propionate_combined_with_ACEI/ARB_in_the_treatment_of_immunoglobulin_A_nephropathy_ DB - PRIME DP - Unbound Medicine ER -
Grapherence [↑20]

Related Citations

More